Vanguard Asset Management’s CorMedix CRMD Stock Holding History

Vanguard Asset Management’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$385K	Hold	49,040	–	–	﹤0.01%	2285
2026 Q1	$333K	Buy	+49,040	New	+$362K	﹤0.01%	2265

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Asset Management's CRMD Position: Q2 2026 in Review

Vanguard Asset Management held its CorMedix (CRMD) position steady in Q2 2026 at 49,040 shares worth $385K. The position accounts for ﹤0.01% of the portfolio, ranked #2285.

Vanguard Asset Management first reported a position in CRMD in Q1 2026 and has held it in 2 quarters since. 175 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

Vanguard Asset Management held 49,040 shares of CorMedix worth $385K as of Q2 2026.
Vanguard Asset Management left its CorMedix share count unchanged in Q2 2026.
CorMedix made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2285 holding.
Vanguard Asset Management first reported a position in CorMedix in Q1 2026 and has held it in 2 quarters since.
175 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.